Title	Role of the Atg9a gene in intrauterine growth and survival of fetal mice
Author(s)	Kojima, Takashi; Yamada, Takahiro; Akaishi, Rina; Furuta, Itsuko; Saitoh, Tatsuya; Nakabayashi, Kazuhiko; Nakayama, Keiichi I.; Nakayama, Keiko; Akira, Shizuo; Minakami, Hisanori
Citation	Reproductive biology, 15(3), 131-138 https://doi.org/10.1016/j.repbio.2015.05.001
Issue Date	2015-09
Doc URL	http://hdl.handle.net/2115/62736
Rights	© 2015. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	http://creativecommons.org/licenses/by-nc-nd/4.0/
Type	article (author version)
File Information	manuscript.pdf

[Instructions for use](#)

Role of the *Atg9a* gene in intrauterine growth and survival of fetal mice

Takashi Kojima^a, Takahiro Yamada^a, Rina Akaishi^a, Itsuko Furuta^a, Tatsuya Saitoh^b, Kazuhiko Nakabayashi^c, Kei-Ichi Nakayama^d, Keiko Nakayama^e, Shizuo Akira^b, Hisanori Minakami

^aDepartment of Obstetrics, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638, Japan; ^bLaboratory of Host Defense, WPI Immunology Frontier Research Centre, Osaka University, Suita, 565-0871, Japan; ^cDivision of Developmental Genomics, Department of Maternal-Fetal Biology, National Centre for Child Health and Development, Tokyo, Japan; ^dDepartment of Molecular and Cellular Biology and Laboratory of Embryonic and Genetic Engineering, Medical Institute of Bioregulation, Kyushu University, Fukuoka, 812-8582, Japan; ^eDivision of Cell Proliferation, Tohoku University School of Medicine, Sendai, 980-8575, Japan

Short title: *Atg9a* gene in murine fetal growth and survival

Corresponding author:

Takahiro Yamada

E-mail address: taka0197@med.hokudai.ac.jp

Phone number: +81-11-706-5941

Current address: N15W7, Kita-ku, Sapporo, 060-8638, Japan

Abstract

Autophagy is activated by environment unfavorable for survival and requires Atg9a protein. Mice heterozygous for $p57^{Kip2}$, devoid of the imprinted paternal allele ($p57^{Kip2+/-}$), are known to develop hypertension during pregnancy. To determine whether fetal *Atg9a* is involved in the intrauterine survival and growth of fetal mice, this study was performed on *Atg9a* heterozygous ($Atg9a^{+/-}$) pregnant mice with and without $p57^{Kip2+/-}$. The pregnant mice heterozygous for both knockout alleles of *Atg9a* and $p57^{Kip2}$ ($Atg9a^{+/-}/p57^{Kip2+/-}$), but not those heterozygous for *Atg9a* alone, developed hypertension during pregnancy. Placental expression of *Atg9a* mRNA was significantly decreased in the $Atg9a^{-/-}$ mice compared to $Atg9a^{+/-}$ or $Atg9a^{+/+}$ mice. The $Atg9a^{-/-}$ fetal mice exhibited significantly retarded growth and were more likely to die *in utero* compared to $Atg9a^{+/+}$ and $Atg9a^{+/-}$ fetal mice. Growth retardation was observed in the presence of maternal hypertension in $Atg9a^{-/-}$ fetal mice. These results suggest that $Atg9a^{-/-}$ fetal mice from pregnant dams heterozygous for both knockout alleles of *Atg9a* and $p57^{Kip2}$ are more susceptible to hypertensive stress than fetuses with intact autophagic machinery.

Key words: Autophagy, Fetal growth restriction, Hypoxia, Intrauterine fetal death, Hypertension

1. Introduction

Autophagy is a bulk degradation system, which controls the clearance and reuse of intracellular constituents, and is important for the maintenance of an amino acid pool essential for survival [1-3]. Autophagy can be activated by nutritional deprivation and intracellular stress, such as hypoxia. Genetic studies in yeast have identified many autophagy-related (*Atg*) genes that are required for autophagosome formation essential for autophagy, such as *Atg3*, *Atg5*, *Atg7*, *Atg9a*, and *Atg16L1* [4]. Most of the *Atg* genes are conserved in higher eukaryotes. In yeast, autophagy-defective mutants were unable to survive under conditions of nitrogen starvation [5]. Similarly, the *Atg3*-, *Atg5*-, *Atg7*-, *Atg9a*-, and *Atg16L1*-knockout mice (genotypes of each *Atg*^{-/-}) did not survive, and usually died within **one** day after birth [6-9]. Thus, autophagy was found to be crucial for survival in the neonatal period [6-10], while mice heterozygous for the knockout allele of the *Atg9a* gene (*Atg9a*^{+/-}) grew normally [9]. Even in the embryonic stages, a shortage of nutrient and oxygen supply from the placenta occurs in human fetuses in certain clinical conditions, such as hypertensive pregnancies and maternal malnutrition, leading to fetal growth restriction (FGR) and intrauterine fetal death (IUFD) [11-13]. Therefore, similar adverse events may occur in response to unfavorable intrauterine environments in fetal mice devoid of autophagic machinery. Indeed, FGR and IUFD have been reported in fetal mice deficient in *beclin 1*, which is another gene essential for autophagy [14].

The *Atg9b* gene - expressed in the placenta - functionally complements *Atg9a* [19]. Therefore, *Atg9b* protein expression may be higher in the placenta of *Atg9a*^{-/-} fetal mice.

When the expression of Atg9b protein is increased, autophagic activity may be monitored by quantifying the expression of LC3-II (truncated protein of LC3-I) in the placenta of *Atg9a*^{-/-} fetal mice.

The p57^{Kip2}, a potent inhibitor of the cyclin-cyclin dependent kinase (CDK) complex, is a paternally imprinted gene located within a cluster of imprinted genes in humans (chromosome 11p15.5) and mice (distal chromosome 7) [15,16]. As p57^{Kip2}^{+/-} (heterozygous, lacking the paternal allele) pregnant mice develop abnormalities similar to preeclampsia, including hypertension and proteinuria when carrying a fetus without p57^{Kip2} expression [17], these mice can be used as an animal model for hypertensive disorders in pregnancy. The present study was performed to determine whether fetal *Atg9a* is involved in survival and *in utero* growth in pregnant mice heterozygous for *Atg9a* (*Atg9a*^{+/-}) with and without p57^{Kip2}^{+/-}. In addition, expressions of *Atg9b* mRNA, Atg9b protein and LC3-II protein were compared between placentas with *Atg9a*^{-/-} and *Atg9a*^{+/+}.

2. Materials and Methods

2.1. Mice

Mice housed in a temperature- and humidity-controlled room were maintained under a 12:12-hour light-dark schedule with free access to food and water. All procedures were performed in accordance with the Local Ethical Commission for Animal Experiments at Hokkaido University (Japan). Female and male mice (129Sv × C57BL/6) heterozygous for *Atg9a* (*Atg9a*^{+/-}) [9] were provided by a co-author (TS). Male mice heterozygous for p57^{Kip2},

lacking the imprinted paternal allele ($p57^{Kip2+/-}$) [18], were provided by co-authors (KN and KN). In the current study, female mice of $Atg9a^{+/-}$ alone were mated with male mice of $p57^{Kip2+/-}$ to generate female mice heterozygous for knockout alleles of $Atg9a$ and $p57^{Kip2}$ ($Atg9a^{+/-}/p57^{Kip2+/-}$). The genotype of generated $Atg9a^{+/-}/p57^{Kip2+/-}$ female was determined by PCR of tail DNA. Female mice of $Atg9a^{+/-}$ and $Atg9a^{+/-}/p57^{Kip2+/-}$ were mated with male mice of $Atg9a^{+/-}$ to generate four embryo groups (groups A1, A2, B1 and B2, Tab. 1) divided according to differences in mother and fetal $Atg9a$ genotypes. Pregnancy stage was expressed as the number of days *post coitum* (dpc). Thirteen pregnant mice with $Atg9a^{+/-}$ and 13 pregnant mice with $Atg9a^{+/-}/p57^{Kip2+/-}$ were used in the study. Pregnant mice of both groups were sacrificed on 13.5, 15.5, and 17.5 dpc for determination of the number of fetuses, measurement of live fetal body weight and determination of fetal $Atg9a$ genotypes by PCR of tail DNA (Fig. 1).

2.2. Measurement of blood pressure in pregnant mice

Blood pressure was measured with a tail-cuff using a CODA™ monitor (Kent Scientific, Torrington, CT, USA), 5 – 10 times at 30 s intervals, 15 min after the behavior and heart rate of the pregnant mice were stabilized in the morning of 5.5, 9.5, 13.5, 15.5, and 17.5 dpc. Blood pressure values are reported as the means of at least three measurements varying by 5% obtained in one session.

2.3. Measurement of fetal body weight

The body weights of pregnant mice and alive fetal mice were measured using Electronic balance FA-200 (A&D, Tokyo, Japan). Pregnant mice were anesthetized deeply with ether and dissected in the lower abdomen. The multilocular uterus containing a fetus in each locus was incised and fetuses with their placentas were separated from the uterus. Some fetuses, based on their color and size, appeared to be dead at sacrifice. Fetuses that were less pinkish and smaller than others were judged as dead (Fig. 1; upper panel). These fetuses were subjected to *Atg9a* genotype determination, but their body weights were not measured.

2.4. DNA extraction, PCR amplification and electrophoresis

The *Atg9a* genotypes of the fetuses (Fig. 1; lower panel) and placentas were analyzed using PCR of fetal tail DNA and placental DNA. The DNA was extracted using a DNA extraction kit (DNeasy[®] Blood & Tissue Kit; Quiagen, Valencia, CA, USA). PCR was performed in a final volume of 15 μ L consisting of 1 μ L of genomic DNA, 1.5 μ L of 10 $\times$ Taq buffer, 1.5 μ L of dNTPs (2.5 mM each), 0.6 μ L each of forward and reverse primers, 9.7 μ L of nuclease-free water, and 0.1 μ L of Taq DNA polymerase, under the following conditions: 3 min at 95°C, 35 cycles at 95°C for 20 s and 68°C for 1 min. The primers for the wild-type allele were:

5'-CCAGAGCCTGTCATGGTACTGGGAACC-3' (primer I) and

5'-CCTCAAGGAGCAGGTGCAGCGAGATGG-3' (primer II). For the knockout allele,

primer I and 5'-CTAAAGCGCATGCTCCAGACTGCCTTG-3' (primer III) were used. The

amplified products were checked by 2.0% agarose gel electrophoresis with ethidium bromide.

The DNA bands were visualized with a UV transilluminator to determine the genotypes (Fig. 1; lower panel).

2.5. Detection of *Atg9b* mRNA expression

The RNA samples were extracted from 20 mg of frozen placental sample using an RNeasy® Plus Mini Kit (Qiagen) after smashing with MicroSmash™ (Tomy Seiko, Tokyo, Japan), and the sample RNA concentrations were measured by NanoDrop® (ND-1000; Thermo Scientific Japan, Kanagawa, Japan). After dilution of each sample with RNase-free water and adjusted to a uniform density (3 µg/µL), reverse-transcription polymerase chain reaction (RT-PCR) was performed with Super Script™ III (Life Technologies, Carlsbad, CA, USA). Quantitative Real-time PCR was used to measure the expression of *Atg9b* mRNA using SYBR® Premix Ex Taq™ (Takara, Shiga, Japan) and an ABI 7300 Real-Time PCR System (PE Applied Biosystems, Foster City, CA, USA). *GAPDH* was used as an internal standard (housekeeping gene). Real-time PCR was performed in a final volume of 15 µL consisting of 0.6 µL of sample cDNA, 7.5 µL of 2x Ex Taq buffer, 0.3 µL of 50x ROX Reference Dye, 0.6 µL each of forward and reverse primers, 5.4 µL of nuclease-free water under the following conditions: for *Atg9a*, 2 min at 50°C, 10 s at 95°C, 40 cycles at 95°C for 15 s and 59°C for 1 min; and for *Atg9b* and *GAPDH*, 2 min at 50°C, 10 s at 95°C, 40 cycles at 95°C for 15 s and 62°C for 1 min. The sequences of primers were 5'-GAGCAGGTGCAGCGAGATG-3' (forward) and 5'-GCAGGTCTCTGGACAGTGAGG-3' (reverse) for *Atg9a*,

124 5'-GCATCACATCCAGAACCTGGA-3' (forward) and
125 5'-CCGCTGATGATAGCTGTAGATCTTG-3' (reverse) for *Atg9b*, and
126 5'-GGCATTGCTCTCAATGACAA-3' (forward) and 5'-TGTGAGGGAGATGCTCAGTG-3'
127 (reverse) for *GAPDH*.

128

129 **2.6. Immunodetection of Atg9b and LC3-II**

130 Western blotting was performed to analyze the expression levels of Atg9b protein and
131 microtubule-associated protein light chain 3 (LC3)-II (truncated protein of LC3-I). The
132 sample proteins were extracted from 20 mg of frozen placental tissues after mixing with 100
133 μ L of 2% Triton X-100 lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 2% Triton X-100, 2
134 mM PMSF, and complete protease inhibitor cocktail), and then sonicated (Handy Sonic[®];
135 Tomy Seiko, Tokyo, Japan), extracted, and the protein concentration was measured by BCA
136 Protein Assay (Thermo Fisher Scientific, Rockford, IL, USA).

137 Aliquots of 12 μ g of protein samples were diluted with 1:2 volumes of Laemmli
138 sample buffer (10% SDS, 1 M DTT, 0.5 M Tris-HCl, pH 6.8, 0.001% bromophenol blue, and
139 5% glycerol), boiled at 95°C for 5 min, separated by SDS-polyacrylamide gel electrophoresis
140 (SDS-PAGE) using 8% gels for Atg9b and 13% for LC3-II, electrotransferred onto PDVF
141 membranes (Amersham Biosciences, Little Chalfont, UK), and blocked with 1.5% skim milk
142 in TBS-T (1 $\times$ TBS with 0.08% Tween) at room temperature for 60 min. The membranes were
143 incubated with the following primary antibodies at 4°C overnight: Atg9b (anti-ATG9B

antibody, 1:1000; NB110-74833; NOVUS, Littleton, CO, USA), LC3-II (anti-LC3, 1:800; MBL, Nagoya, Japan). GAPDH was also detected as a loading control in this study using an anti-GAPDH mouse IgG antibody at a dilution of $1:4 \times 10^6$.

After washing with TBS-T, the membranes were incubated with secondary antibody at room temperature for 60 min. ECL™ anti-rabbit IgG, horseradish peroxidase-conjugated whole antibody (1:10000; GE Healthcare, Little Chalfont, UK) was used for Atg9b and LC3-II, and ECL™ anti-mouse IgG, horseradish peroxidase-conjugated whole antibody (1:10000; GE Healthcare) for GAPDH. The protein bands were visualized with ECL solution (Immobilon™ Western, Chemiluminescent HRP Substrate; Millipore, Little Chalfont, UK) and quantified with ImageQuant LAS4000 (GE Healthcare Japan, Tokyo, Japan).

2.7. Statistical analysis

Data are presented as mean±standard deviation. Statistical analysis was performed using the JMP® Pro 11 statistical software package (SAS, Cary, NC, USA). Differences between two groups were tested using the Mann-Whitney U test (Figs. 2, 5, and 6). Differences between more groups were tested using the Steel-Dwass test after confirmation of significant difference with Kruskal-Wallis test (Figs. 3, 4, and 7). Differences between frequencies were tested using Fisher's exact test with Bonferroni correction (Table 2). In all analyses, $P < 0.05$ was taken to indicate statistical significance.

3. Results

165 *Atg9a*^{+/-} mice (used to obtain A1 and A2 groups, Tab. 1) did not exhibit significant changes in
 166 systolic blood pressure (SBP) during pregnancy (Fig. 2), while *Atg9a*^{+/-}/*p57*^{Kip2 +/-} mice (used
 167 to obtain B1 and B2 groups, Tab. 1) exhibited a significant increase in SBP at 9.5 dpc (113 ±
 168 11.6 mm Hg) and thereafter (116 ± 12.6, 125 ± 16.2, and 121 ± 12.8 mm Hg for 13.5, 15.5,
 169 and 17.5 dpc, respectively) compared to SBP baseline (102 ± 12.0 mm Hg) determined before
 170 pregnancy. The SBP differed significantly between the two groups (A vs. B) at 9.5 dpc (113 ±
 171 11.6 vs. 99 ± 9.5 mm Hg), 15.5 dpc (125 ± 16.2 vs. 95 ± 10.5 mm Hg), and 17.5 dpc (121 ±
 172 12.8 vs. 102 ± 12.1 mm Hg). Pre-pregnancy body weight did not differ significantly between
 173 female mice of *Atg9a*^{+/-} (normotensive pregnancy [A] group; n=13; Tab. 1) and *Atg9a*
 174 ^{+/-}/*p57*^{Kip2 +/-} (hypertensive pregnancy group [B]; n=13) groups (22.8 ± 2.7 vs. 21.7 ± 2.5 g,
 175 respectively).

176 The expression of *Atg9a* mRNA was significantly reduced in *Atg9a*^{-/-} placentas
 177 compared to *Atg9a*^{+/-} and *Atg9a*^{+/+} placentas (Fig. 3). Then, placental expression of *Atg9b*
 178 mRNA, Atg9b protein and LC-3-II protein (Fig. 4) were analyzed in relation to placental
 179 *Atg9a* genotype (*Atg9a*^{+/+} vs. *Atg9a*^{-/-}) and the presence or absence of gene *p57*^{Kip2 +/-}
 180 (indicative of hypertension). The *Atg9b* mRNA expression in *Atg9a*^{-/-} placentas was
 181 comparable to that of *Atg9a*^{+/+} placentas. However, in the presence of hypertension, the *Atg9b*
 182 mRNA level was significantly higher in *Atg9a*^{+/+} placentas than that in *Atg9a*^{-/-} placentas. The
 183 expression of Atg9b and LC3-II proteins was significantly higher in *Atg9a*^{-/-} placentas than in
 184 *Atg9a*^{+/+} placentas in the presence of hypertension (Fig. 4).

185 The *Atg9a*^{+/+}, *Atg9a*^{+/-}, and *Atg9a*^{-/-} fetal mice accounted for 30% (69/231), 53%

(123/231), and 17% (39/231) of the total number of fetuses, respectively, with the number of *Atg9a*^{-/-} fetal mice lower than the expected Mendelian frequency (Tab. 2). The fraction of dead fetal mice appeared to be greater with decreasing number of fetal *Atg9a* alleles: 1.4% (1/69), 14% (17/123), and 26% (10/39) for *Atg9a*^{+/+}, *Atg9a*^{+/-}, and *Atg9a*^{-/-} fetuses, respectively. The prevalence rate of IUFD was significantly higher in *Atg9a*^{-/-} fetal mice than in *Atg9a*^{+/+} fetal mice (26% [10/39] vs. 1.4% [1/69]) and in fetal mice with at least one *Atg9a* allele (*Atg9a*^{+/+} + *Atg9a*^{+/-}) (26% [10/39] vs. 9.4% [18/192]).

The fetal body weight was significantly lower in fetuses carried by hypertensive dams than those of normotensive dams (B1 and B2 < A1 and A2) at all stages of pregnancy (Fig. 5). The fetal body weight was also significantly lower in *Atg9a*^{-/-} fetal mice (groups A2+B2) than in *Atg9a*^{+/+} and *Atg9a*^{+/-} fetal mice (groups A1+B1) on 13.5 and 17.5 dpc (Fig. 6). Finally, the body weight of fetuses carried by hypertensive dams was usually lower than that of fetuses of normotensive dams (Fig. 7). At any stage of pregnancy, fetal body weight did not differ between the groups carried by normotensive dams (A1 vs. A2). In contrast, body weight of fetuses carried by hypertensive dams was significantly lower in group B2 than in group B1 on 15.5 and 17.5 dpc (Fig. 7).

4. Discussion

The current study demonstrated that the growth of *Atg9a*^{-/-} fetal mice was retarded compared with *Atg9a*^{+/+} and *Atg9a*^{+/-} fetal mice. This confirmed the results of previous studies in which autophagy-defective fetal mice devoid of *Atg* genes other than *Atg9a* were born with lower

birth weight than those with normal (in relation to autophagy) phenotype [6,7,10]. In addition, it was suggested that *Atg9a*-knockout fetal mice are characterized by an increased likelihood of dying *in utero*, as it was reported for *beclin 1*-knockout fetal mice [14].

Since in mice autophagy remains at a low level throughout the embryonic period and massive autophagy occurs transiently soon after birth in normal neonatal mice, autophagy was suggested to play minor role in fetal mouse development [6]. Therefore, fetal growth restriction of *Atg9a*-knockout fetal mice has not been emphasized in previous reports [6,7,10]. The body weights of *Atg3*^{-/-}, *Atg5*^{-/-}, and *Atg7*^{-/-} neonatal mice were significantly lower than those of wild-type and heterozygous mice [6,7,10]. As all *Atg3*^{-/-}, *Atg5*^{-/-}, *Atg7*^{-/-}, and *Atg9a*^{-/-} mice are indeed defective in autophagy [6,7,9,10], these results suggest that the lack of functional autophagic machinery in fetuses resulted in a lower birth weight. Thus, the fetal autophagic machinery has a protective function against FGR. This notion was further supported by our findings that FGR was observed in *Atg9a*^{-/-} fetal mice carried by hypertensive dams.

Although in the current study, the fetus size in normotensive dams did not differ significantly among different fetal *Atg9a* genotype, the Atg9b and LC3-II proteins were present in the placentas of *Atg9a*^{-/-} fetal mice. The placental autophagy may have prevented FGR in *Atg9a*^{-/-} fetal mice carried by normotensive dams. The deleterious effect of hypertension in addition to the lack of fetal autophagy, in turn, may have outweighed the protective effect of placental autophagy on FGR in fetuses carried by hypertensive dams.

Maternal hypertension is a well-known detrimental factor for pregnancy outcome,

causing FGR and IUFD in humans [12]. Placental insufficiency due to poor blood supply *via* the uterine arteries is the most common cause of fetal starvation, and the increased impedance to flow within uterine arteries occurs frequently in hypertensive disorders in pregnancy [11,13]. In such an unfavorable intrauterine environment, fetal autophagy may be activated, and placental autophagy was indeed increased in women with hypertensive disorders and/or FGR [20-24]. In addition, the expression of LC3-II protein in the human placenta tended to linearly increase with a decreasing normalized infant birth weight [24]. The findings in humans and mice suggest that dysfunction of the fetal autophagic machinery is causally associated with FGR, and an unfavorable intrauterine environment such as maternal hypertension outweighs the protective role of fetal autophagy in FGR, leading to FGR even after the activation of autophagy.

The *Atg9a*^{-/-} fetal mice had a high likelihood of *in utero* death in the present study. In addition, the frequency of *Atg9a*^{-/-} fetal mice was somewhat lower than the expected Mendelian frequency, even after including dead fetuses. Similar findings, but with a more severe phenotype, were reported in *beclin 1*-knockout fetal mice. No homozygous mutant offspring (*beclin 1*^{-/-}) were born to dams heterozygous for *beclin 1* because all *beclin 1*^{-/-} fetal mice had severely retarded growth and died in the early embryonic stages [14]. Such early-dead fetuses become conceptus traces and are not recognized as fetuses [14]. These early embryonic deaths may help to explain why less *Atg9a*^{-/-} fetal mice than expected were observed in the current study. In addition, strict classification of fetal mice as dead or alive was not easy and was based on color and size. Therefore, some fetal mice classified as dead

249 might have been alive.

250 In conclusion, in the current study we have focused on the examination of the
251 effects of *Atg9a* deficiency in fetal mice on fetal growth and survival. We demonstrated that
252 *Atg9a*-knockout (*Atg9a*^{-/-}) fetal mice were likely to show growth restriction, especially in the
253 presence of maternal hypertension. This suggests that dysfunction of fetal autophagic
254 machinery causes lower fetal body weight. In addition, the results of the study indicated that
255 fetal mice devoid of *Atg9a* had an increased likelihood of dying *in utero*, similar to the
256 observations reported previously for autophagy-defective *beclin 1*^{-/-} mice [14].

257

258 **Conflict of Interest**

259 None declared.

260

261

262 **References**

- 263 [1] Mizushima N, Ohsumi Y, Yoshimori T: Autophagosome formation in mammalian cells.
264 Cell Struct Funct 2002, 27:421-429.
- 265 [2] Lum JJ, DeBerardinis RJ, Thompson CB: Autophagy in metazoans: cell survival in the
266 land of plenty. Nat Rev Mol Cell Biol 2005, 6:439-448.
- 267 [3] Xie Z, Klionsky DJ: Autophagosome formation: core machinery and adaptations. Nat Cell
268 Biol 2007, 9:1102-1109.
- 269 [4] Klionsky DJ, Cregg JM, Dunn WA, Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani
270 S, Thumm M, Veenhuis M, Ohsumi Y: A unified nomenclature for yeast
271 autophagy-related genes. Dev Cell 2003, 5:539-545.
- 272 [5] Tsukada M, Ohsumi Y: Isolation and characterization of autophagy-defective mutants of
273 *Saccharomyces cerevisiae*. FEBS Lett 1993, 333:169-174.
- 274 [6] Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y,
275 Tokuhisa T, Mizushima N: The role of autophagy during the early neonatal starvation
276 period. Nature 2004, 432:1032-1036.
- 277 [7] Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N,
278 Ohsumi Y, Uchiyama Y, et al: Impairment of starvation-induced and constitutive
279 autophagy in Atg7-deficient mice. J Cell Biol 2005, 169:425-434.
- 280 [8] Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, Omori H, Noda T,
281 Yamamoto N, Komatsu M, et al: Loss of the autophagy protein Atg16L1 enhances
282 endotoxin-induced IL-1beta production. Nature 2008, 456:264-268.

- 283 [9] Saitoh T, Fujita N, Hayashi T, Takahara K, Satoh T, Lee H, Matsunaga K, Kageyama S,
284 Omori H, Noda T, et al: Atg9a controls dsDNA-driven dynamic translocation of STING
285 and the innate immune response. *Proc Natl Acad Sci U S A* 2009, 106:20842-20846.
- 286 [10] Sou YS, Waguri S, Iwata J, Ueno T, Fujimura T, Hara T, Sawada N, Yamada A,
287 Mizushima N, Uchiyama Y, et al: The Atg8 conjugation system is indispensable for
288 proper development of autophagic isolation membranes in mice. *Mol Biol Cell* 2008,
289 19:4762-4775.
- 290 [11] Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH: One-stage screening
291 for pregnancy complications by color Doppler assessment of the uterine arteries at 23
292 weeks' gestation. *Obstet Gynecol* 2000, 96:559-564.
- 293 [12] Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R: Pre-eclampsia. *Lancet* 2010,
294 376:631-644.
- 295 [13] Contro E, Cha DH, De Maggio I, Ismail SY, Falcone V, Gabrielli S, Farina A: Uterine
296 artery Doppler longitudinal changes in pregnancies complicated with intrauterine growth
297 restriction without preeclampsia. *Prenat Diagn* 2014.
- 298 [14] Yue Z, Jin S, Yang C, Levine AJ, Heintz N: Beclin 1, an autophagy gene essential for
299 early embryonic development, is a haploinsufficient tumor suppressor. *Proc Natl Acad*
300 *Sci U S A* 2003, 100:15077-15082.
- 301 [15] Hatada I, Mukai T: Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in
302 mouse. *Nat Genet* 1995, 11:204-206.
- 303 [16] Matsuoka S, Thompson JS, Edwards MC, Bartlett JM, Grundy P, Kalikin LM, Harper

304 JW, Elledge SJ, Feinberg AP: Imprinting of the gene encoding a human cyclin-dependent
 305 kinase inhibitor, p57KIP2, on chromosome 11p15. *Proc Natl Acad Sci U S A* 1996,
 306 93:3026-3030.

307 [17] Kanayama N, Takahashi K, Matsuura T, Sugimura M, Kobayashi T, Moniwa N, Tomita
 308 M, Nakayama K: Deficiency in p57Kip2 expression induces preeclampsia-like symptoms
 309 in mice. *Mol Hum Reprod* 2002, 8:1129-1135.

310 [18] Takahashi K, Nakayama K: Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal
 311 abnormalities and growth retardation. *J Biochem* 2000, 127:73-83.

312 [19] Yamada T, Carson AR, Caniggia I, Umebayashi K, Yoshimori T, Nakabayashi K,
 313 Scherer SW: Endothelial nitric-oxide synthase antisense (NOS3AS) gene encodes an
 314 autophagy-related protein (APG9-like2) highly expressed in trophoblast. *J Biol Chem*
 315 2005, 280:18283-18290.

316 [20] Oh SY, Choi SJ, Kim KH, Cho EY, Kim JH, Roh CR: Autophagy-related proteins, LC3
 317 and Beclin-1, in placentas from pregnancies complicated by preeclampsia. *Reprod Sci*
 318 2008, 15:912-920.

319 [21] Hung TH, Chen SF, Lo LM, Li MJ, Yeh YL, Hsieh TT: Increased autophagy in
 320 placentas of intrauterine growth-restricted pregnancies. *PLoS One* 2012, 7:e40957.

321 [22] Chang YL, Wang TH, Chang SD, Chao AS, Hsieh PC, Wang CN: Increased autophagy
 322 in the placental territory of selective intrauterine growth-restricted monochorionic twins.
 323 *Prenat Diagn* 2013, 33:187-190.

324 [23] Curtis S, Jones CJ, Garrod A, Hulme CH, Heazell AE: Identification of autophagic

325 vacuoles and regulators of autophagy in villous trophoblast from normal term
326 pregnancies and in fetal growth restriction. J Matern Fetal Neonatal Med 2013,
327 26:339-346.

328 [24] Akaishi R, Yamada T, Nakabayashi K, Nishihara H, Furuta I, Kojima T, Morikawa M,
329 Fujita N, Minakami H: Autophagy in the placenta of women with hypertensive disorders
330 in pregnancy. Placenta 2014, 35:974-980.

331

332

Figure captions

Fig. 1. Exemplary images of fetuses at 17.5 day post coitum. A/ *Atg9a*^{-/-} fetuses judged as dead, B/ *Atg9a*^{-/-} fetuses with growth retardation, C/ *Atg9a*^{+/+} fetuses with normal growth. The *Atg9a* genotypes of the fetuses were determined by PCR of mouse tail DNA according to the presence or absence of wild type (WT) and knockout (KO) alleles.

Fig. 2. Systolic blood pressure (mean $\pm$ SD) in *Atg9a*^{+/-}/*p57*^{Kip+/-} and *Atg9a*^{+/-} pregnant mice. The numbers of pregnant mice are indicated in parentheses. **P* < 0.05 between the two examined groups of mice; †*P* < 0.05 between a particular day post coitum (dpc) and a pre-pregnancy day (SBP baseline).

Fig. 3. Expression of *Atg9a* mRNA in the placentas of *Atg9a*^{+/+}, *Atg9a*^{+/-} and *Atg9a*^{-/-} mice. The mice were sacrificed at 15.5 day post coitum; the numbers of pregnant mice are indicated in parentheses. Different superscripts mean significant differences (*P* < 0.05).

Fig. 4. Expression of *Atg9b* mRNA, Atg9b protein and LC3-II protein in placentas with *Atg9a*^{+/+} and *Atg9a*^{-/-} genotypes. The pregnant mice were sacrificed at 17.5 day post coitum. Please refer to Table 1 for group (A1, A2, B1, and B2) definition. Different superscripts mean significant differences (*P* < 0.05).

352

353 Fig. 5. Fetal body weight in the A1+A2 (normotensive) and B1+B2 (hypertensive) mice on
354 13.5, 15.5, and 17.5 days post coitum (dpc). Numbers of fetuses are presented in parentheses.
355 Upper and lower ends of the box and horizontal line inside the box indicate 75th percentile,
356 25th percentile, and median values, respectively. $*P < 0.05$ between the two compared groups.
357 Please refer to Table 1 for group (A1, A2, B1, and B2) definition.

358

359 Fig. 6. Fetal body weight in the A1+B1 and A2+B2 mice on 13.5, 15.5, and 17.5 days post
360 coitum (dpc). Numbers of fetuses are presented in parentheses. Upper and lower ends of the
361 box and horizontal line inside the box indicate 75th percentile, 25th percentile, and median
362 values, respectively. $*P < 0.05$ between the two compared groups. Please refer to Table 1 for
363 group (A1, A2, B1, and B2) definition.

364

365 Fig. 7. Fetal body weight in the A1, A2, B1 and B2 mice on 13.5, 15.5, and 17.5 days post
366 coitum (dpc). Numbers of fetuses are presented in parentheses. Upper and lower ends of the
367 box and horizontal line inside the box indicate 75th percentile, 25th percentile, and median
368 values, respectively. $*P < 0.05$ between the two compared groups. Please refer to Table 1 for
369 group (A1, A2, B1, and B2) definition.

370

371

372 Fig. 1.

373

374

375 Fig. 2.

376

377

378

379 Fig. 3.

380

381

382

383 Fig. 4.

384

385

386

387 Fig. 5.

388

389

390

391 Fig. 6.

392

393

Table 1. Mating patterns and fetal *Atg9a* genotype

Mating (male × female)		Fetal genotype
Group A1	<i>Atg9a</i> ^{+/-} × <i>Atg9a</i> ^{+/-}	<i>Atg9a</i> ^{+/+} , <i>Atg9a</i> ^{+/-}
Group A2	<i>Atg9a</i> ^{+/-} × <i>Atg9a</i> ^{+/-}	<i>Atg9a</i> ^{-/-}
Group B1	<i>Atg9a</i> ^{+/-} × <i>Atg9a</i> ^{+/-} /p57 ^{Kip2} +/ -*	<i>Atg9a</i> ^{+/+} , <i>Atg9a</i> ^{+/-}
Group B2	<i>Atg9a</i> ^{+/-} × <i>Atg9a</i> ^{+/-} /p57 ^{Kip2} +/ -*	<i>Atg9a</i> ^{-/-}

*p57^{Kip2} +/ -: heterozygous, devoid of the imprinted paternal allele

Table 2. Effects of fetal *Atg9a* genotype on the number of live or dead fetal mice and the intrauterine fetal death (IUFD) rate

Dams: <i>Atg9a</i> ^{+/-} (normotensive group)				
Fetal genotype	n	<i>Atg9a</i> ^{+/+} (A1)	<i>Atg9a</i> ^{+/-} (A1)	<i>Atg9a</i> ^{-/-} (A2)
13.5 dpc	4	12/0	11/3	4/0
15.5 dpc	4	21/0	16/3	10/1
17.5 dpc	5	14/1	31/2	2/6
IUFD rate		2.1% (1/48)	12% (8/66)	30% (7/23)
Dams: <i>Atg9a</i> ^{+/-} /p57 ^{Kip2} ^{+/-} (hypertensive group)				
Fetal genotype	n	<i>Atg9a</i> ^{+/+} (B1)	<i>Atg9a</i> ^{+/-} (B1)	<i>Atg9a</i> ^{-/-} (B2)
13.5 dpc	2	3/0	8/0	5/0
15.5 dpc	6	9/0	24/4	3/1
17.5 dpc	5	9/0	16/5	5/2
IUFD rate		0.0% (0/21)	16% (9/57)	19% (3/16)
Overall number of fetuses		69 (68/1)	123 (106/17)	39 (29/10)
Overall IUFD rate		1.4% (1/69) ^a	14% (17/123) ^b	26% (10/39) ^c

dpc - day *post coitum*; n - number of dams sacrificed.

P < 0.05 for a vs. b, a vs. c; and a + b (18/192) vs. c; Fisher's exact test with Bonferroni correction.